Fact-checked by Grok 2 weeks ago

Pethidine

Pethidine, also known as meperidine and marketed under the brand name Demerol, is a synthetic opioid analgesic belonging to the phenylpiperidine class, primarily indicated for the relief of moderate to severe acute pain when alternative treatments are inadequate.^[1] It exerts its effects through agonism at μ-opioid receptors in the central nervous system, providing analgesia, sedation, and antitussive properties, while also exhibiting anticholinergic, antispasmodic, and local anesthetic activities via sodium channel blockade.^[1] As a Schedule II controlled substance under the U.S. Controlled Substances Act, pethidine carries a high potential for abuse, addiction, and overdose, necessitating careful monitoring and limited use.^[1] Developed in Germany in the late 1930s initially for its anticholinergic effects, pethidine's potent analgesic properties were soon recognized, leading to its widespread adoption in the mid-20th century as an alternative to morphine for perioperative and postoperative pain management.^[2] It is available in oral, intramuscular, subcutaneous, and intravenous formulations, with typical adult dosing ranging from 50 to 150 mg every 3 to 4 hours, not exceeding 600 mg per day to minimize toxicity risks.^[3] Pharmacokinetically, pethidine has an oral bioavailability of approximately 50%, a half-life of 3 to 8 hours, and is metabolized primarily by CYP3A4 and CYP2B6 enzymes in the liver to its active metabolite normeperidine, which has a longer half-life of about 15 to 30 hours and is excreted renally.^[1] Off-label uses include the treatment of postoperative shivering due to its κ-opioid receptor activity and as an adjunct in labor analgesia, though evidence supports morphine or other opioids as superior alternatives in many cases.^[1]^[4] Despite its efficacy, pethidine's clinical utility has declined due to significant adverse effects, including respiratory depression, nausea, dizziness, constipation, and pruritus, which occur at rates comparable to or higher than other opioids.^[3] A major concern is neurotoxicity from normeperidine accumulation, particularly in patients with renal impairment, leading to seizures, myoclonus, and delirium; this risk prompted its removal from the World Health Organization's List of Essential Medicines in 2003 and restrictions in many guidelines against its use for chronic pain or in the elderly.^[1] Contraindications include hypersensitivity, acute asthma, gastrointestinal obstruction, and concurrent use of monoamine oxidase inhibitors (MAOIs) within 14 days, due to the potential for severe serotonin syndrome or hypertensive crisis.^[3] In overdose, symptoms such as miosis, hypotension, and coma are managed with naloxone, supportive ventilation, and, in cases of normeperidine toxicity, hemodialysis.^[1] Overall, while pethidine remains available for short-term acute pain relief in controlled settings, safer opioid alternatives are preferred in contemporary practice to mitigate its unique toxicity profile.^[1]

Medical Uses

Pain Relief Applications

Pethidine, a synthetic opioid analgesic, is primarily indicated for the management of moderate to severe acute pain, including postoperative pain following surgical procedures, labor pain during childbirth, and pain associated with traumatic injuries.^[1]^[5] It provides effective relief by acting on mu-opioid receptors in the central nervous system, offering an alternative when non-opioid analgesics are insufficient.^[1] Clinical guidelines recommend its use in settings requiring short-term analgesia, such as emergency departments or recovery rooms, where rapid onset is beneficial.^[1] Pethidine can be administered via multiple routes to suit clinical needs, including intramuscular (IM), intravenous (IV), subcutaneous (SC), and oral, with IM and IV being the most common for acute pain scenarios due to faster absorption.^[6]^[7] For adults, the typical dosing regimen is 50-150 mg every 3-4 hours as needed, adjusted based on pain severity, patient response, and renal function to avoid accumulation of its metabolite normeperidine.^[6]^[8] Lower doses, such as 25-50 mg IV, may be used initially in elderly or debilitated patients to minimize risks.^[6] Historically, pethidine has been a preferred agent for labor analgesia in countries like the United Kingdom and New Zealand, where intramuscular administration is routinely offered in over 95% of surveyed hospitals for intrapartum pain relief.^[9] Studies indicate that pethidine provides comparable short-term pain reduction to morphine during labor, though women report lower satisfaction with analgesia three days postpartum when using pethidine compared to morphine (relative risk 0.87, 95% CI 0.78-0.98).^[10] This preference stems from its rapid onset and perceived lower risk of respiratory depression in neonates at standard doses, despite concerns over fetal heart rate variability.^[11] Historically, pethidine was favored for pain management in diverticulitis due to its anticholinergic properties, which help reduce intestinal intraluminal pressure and alleviate bowel spasms associated with colonic inflammation.^[12]^[13] Early clinical recommendations highlighted its dual analgesic and spasmolytic effects, making it suitable for acute exacerbations where hypermotility exacerbates discomfort.^[13] However, contemporary guidelines do not preferentially recommend pethidine over other opioids, as evidence indicates no significant risk of spasm with alternatives like morphine.^[12] This application leverages pethidine's ability to relax smooth muscle, providing targeted relief without solely relying on opioid-mediated analgesia.^[13]

Other Therapeutic Indications

Pethidine is employed to prevent and treat shivering during therapeutic hypothermia after cardiac arrest, as it effectively depresses the shivering threshold through stimulation of kappa-opioid receptors.^[14] Among opioids, it demonstrates superior efficacy, reducing the shivering threshold nearly twice as much as the vasoconstriction threshold, making it a key agent in targeted temperature management protocols.^[15] In labor and delivery, pethidine functions as an adjunct analgesic, particularly in regions where epidural access is limited, helping to alleviate pain and provide sedation that may reduce maternal anxiety while augmenting other forms of analgesia.^[16] Low doses (up to 50 mg intramuscularly or intravenously) are associated with minimal neonatal respiratory depression or low Apgar scores, though higher doses can lead to infant respiratory issues and decreased alertness; it remains favored in parts of Asia, Africa, and Latin America due to its low cost and ease of administration.^[16]^[17] Pethidine has limited veterinary applications for pain management in animals, primarily due to its short duration of action and potential for adverse effects like central nervous system excitation.^[18] In species such as horses, a dose of 0.5 mg/kg intravenously may offer brief analgesia for up to 45 minutes, but higher doses (1.0 mg/kg) are not recommended owing to inconsistent efficacy and side effects; dosing must be adjusted based on species, with lower ranges (e.g., 2-10 mg/kg intramuscularly or subcutaneously in dogs and cats) used cautiously where longer-acting opioids are unavailable.^[18]^[19] Pethidine was removed from the World Health Organization's Model List of Essential Medicines in 2003 because of its inferior safety profile compared to alternatives like morphine, primarily due to the neurotoxic metabolite normeperidine that risks seizures and delirium.^[20] As of 2025, it is not included on the list and is not recommended for routine use, with safer opioids preferred globally.^[1]^[20]

Pharmacology

Mechanism of Action

Pethidine, also known as meperidine, primarily exerts its analgesic effects by acting as an agonist at the μ-opioid receptors in the central nervous system, where it binds to these G-protein-coupled receptors to inhibit the release of neurotransmitters involved in pain transmission, such as substance P and glutamate, thereby reducing the perception of pain.^[1] This μ-opioid receptor activation mimics the action of endogenous opioids like endorphins, leading to hyperpolarization of neurons through decreased cyclic AMP levels and increased potassium conductance.^[21] In addition to its opioid activity, pethidine exhibits anticholinergic effects by antagonizing muscarinic acetylcholine receptors, which contributes to smooth muscle relaxation in the gastrointestinal and respiratory tracts, potentially aiding in the relief of associated spasms or secretions.^[22] It also possesses local anesthetic properties through blockade of voltage-gated sodium channels, preventing the propagation of action potentials in nerve fibers, a mechanism shared with other phenylpiperidine derivatives like fentanyl.^[23] Pethidine demonstrates some agonism at κ-opioid receptors, which is thought to underlie its antishivering effects by modulating thermoregulatory pathways in the hypothalamus, distinct from its primary μ-mediated analgesia.^[24] Its activity at δ-opioid receptors is weaker and contributes minimally to its overall pharmacological profile.^[1] Uniquely among opioids, pethidine inhibits the reuptake of serotonin by blocking the serotonin transporter (SERT), thereby increasing synaptic serotonin levels, which can enhance analgesia but also predisposes to risks such as serotonin syndrome when combined with other serotonergic agents.^[25] Its active metabolite, norpethidine, further amplifies serotonergic effects.^[1]

Pharmacokinetics

Pethidine exhibits rapid absorption following oral administration, with a bioavailability of 50-60% in individuals with normal hepatic function, reaching peak plasma concentrations within 1-2 hours. Intravenous administration provides an immediate onset of action, with peak effects occurring within minutes.^[26]^[5] The drug is moderately bound to plasma proteins at approximately 65-75%, primarily to albumin and α1-acid glycoprotein, and distributes widely throughout the body with a volume of distribution of 3-4 L/kg. The elimination half-life of pethidine itself ranges from 3-5 hours in healthy adults.^[5] Pethidine is primarily metabolized in the liver through N-demethylation to the active metabolite norpethidine, catalyzed mainly by the cytochrome P450 enzymes CYP2B6, CYP3A4, and to a lesser extent CYP2C19; norpethidine has an elimination half-life of approximately 15 to 30 hours and possesses neurotoxic properties at higher concentrations.^[27]^[1] Excretion occurs predominantly via the kidneys, with only about 5% of the parent drug eliminated unchanged and the majority as metabolites; renal impairment can lead to accumulation of norpethidine, increasing the risk of toxicity.^[5]^[3] Pharmacokinetic parameters are influenced by several factors, including age—where elimination is slower in the elderly due to increased volume of distribution and higher free fraction—hepatic function, which in cases of impairment like cirrhosis raises bioavailability to 80-90% and extends the half-life, and repeated dosing, which promotes norpethidine accumulation due to its longer half-life.^[3]^[5]

Adverse Effects

Common Side Effects

Pethidine, an opioid analgesic, frequently induces gastrointestinal side effects primarily through its inhibition of gastrointestinal motility. Nausea and vomiting are among the most common, occurring in approximately 22% of patients in clinical settings. Constipation is also prevalent due to the same opioid-mediated reduction in gut peristalsis.^[28]^[1] Central nervous system effects are similarly frequent, arising from pethidine's activation of opioid receptors as well as its anticholinergic activity. These include dizziness, sedation, and euphoria, which can impair alertness and coordination. Dry mouth, another anticholinergic manifestation, affects many users and contributes to discomfort during treatment.^[1]^[29] Additional common reactions encompass sweating, urinary retention, and pruritus (itching), which are generally mild and transient. Sweating and pruritus occur as frequent autonomic responses to opioid administration, while urinary retention results from opioid effects on bladder function. In specific contexts, such as spinal anesthesia, pruritus has been noted in up to 20% of cases.^[29]^[30]^[31] Management of these side effects focuses on symptomatic relief and preventive measures. Antiemetics, such as metoclopramide or ondansetron, are often employed to alleviate nausea and vomiting. For constipation, laxatives or stool softeners are recommended to promote bowel regularity. Patients experiencing dizziness or sedation should rise slowly from sitting or lying positions to minimize fall risk, and adequate hydration can help mitigate dry mouth.^[1]^[29]

Serious Adverse Reactions

Overdose of pethidine can lead to severe respiratory depression, hypotension, and progression to coma, circulatory collapse, cardiac arrest, apnea, and potentially death.^[1]^[32] These effects stem from the opioid's potent mu-receptor agonism, which suppresses central respiratory drive and cardiovascular function at high doses.^[1] Prolonged use of pethidine risks neuroexcitation due to accumulation of its metabolite normeperidine, which can cause seizures, myoclonus, tremors, delirium, and hallucinations.^[1]^[33] This toxicity arises particularly after repeated dosing, as normeperidine exhibits convulsant properties distinct from the parent drug's analgesia.^[34] Pethidine also inhibits serotonin reuptake, increasing the risk of serotonin syndrome, characterized by hyperthermia, muscle rigidity, autonomic instability, and seizures, especially when combined with other serotonergic agents.^[35]^[36] In elderly patients or those with renal impairment, pethidine and normeperidine accumulate due to reduced clearance, heightening the risk of neurotoxicity and other adverse events.^[1]^[37] These concerns contributed to a decline in pethidine use in the United States over the late 20th century, as safer alternatives gained preference amid recognition of its unfavorable risk-benefit profile.^[38] Maternal administration during labor can cross the placenta, causing neonatal respiratory depression, low Apgar scores, and sedation in the newborn.^[39]^[40] As of 2025, regulatory warnings emphasize pethidine's potential for addiction, misuse, and abuse, akin to other opioids, with risks of overdose and death; it carries a boxed warning for these hazards and is recommended only when benefits outweigh dangers.^[1]^[32]

Drug Interactions

Interactions with Other Drugs

Pethidine, also known as meperidine, exhibits significant pharmacodynamic and pharmacokinetic interactions with various classes of drugs, potentially leading to enhanced toxicity or reduced efficacy. One of the most critical interactions occurs with monoamine oxidase inhibitors (MAOIs), such as phenelzine and tranylcypromine. Concomitant administration or use within 14 days of discontinuing an MAOI can precipitate a severe excitatory reaction characterized by hyperpyrexia, convulsions, coma, severe respiratory depression, cyanosis, and hypotension.^[41] This interaction is contraindicated due to its life-threatening nature, as exemplified by the 1984 Libby Zion case, where an 18-year-old patient on phenelzine developed fatal serotonin syndrome following intramuscular pethidine administration for chills.^[42]^[43] Pethidine also increases the risk of serotonin syndrome when combined with serotonergic agents, owing to its metabolite normeperidine's weak inhibition of serotonin reuptake. This syndrome manifests as agitation, hyperthermia, tremors, and potentially seizures or neurotoxicity. Specific examples include selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine, and other agents like tramadol, which can synergistically elevate serotonin levels.^[1]^[44] Clinicians must monitor for symptoms and discontinue therapy if serotonin syndrome is suspected, as the interaction can be fatal in severe cases.^[41] Interactions with central nervous system (CNS) depressants further compound pethidine's risks by potentiating sedation and respiratory depression. Drugs such as benzodiazepines (e.g., diazepam), other opioids, and alcohol amplify these effects, potentially leading to profound sedation, coma, or death.^[1]^[41] To mitigate this, concurrent use should be limited to the lowest effective doses and durations, with close patient monitoring for signs of respiratory compromise.^[41] Pharmacokinetically, pethidine is metabolized primarily by CYP3A4, making it susceptible to interactions with inhibitors of this enzyme. Agents like ketoconazole or erythromycin can reduce pethidine clearance, elevating plasma levels and increasing the risk of toxicity, including fatal respiratory depression or overdose.^[41] Conversely, CYP3A4 inducers such as rifampin may decrease pethidine concentrations, potentially leading to reduced analgesia or withdrawal symptoms upon discontinuation of the inducer. Dosage adjustments and vigilant monitoring are essential in these scenarios to prevent adverse outcomes.^[41]

Contraindications and Precautions

Pethidine is contraindicated in patients with known hypersensitivity to the drug or any of its components, as this may lead to severe allergic reactions including anaphylaxis.^[6] It is also absolutely contraindicated in individuals with significant respiratory depression, due to the risk of life-threatening exacerbation.^[6] Acute or severe bronchial asthma in an unmonitored setting or without access to resuscitative equipment represents another contraindication, as pethidine can worsen respiratory compromise.^[6] Additionally, known or suspected gastrointestinal obstruction, including paralytic ileus, prohibits its use, given the potential for delayed gastric emptying and further obstruction.^[6] Caution is advised in patients with renal or hepatic impairment, where the active metabolite normeperidine can accumulate, increasing the risk of neurotoxicity such as seizures and delirium; dosage should be titrated slowly with close monitoring.^[1] Elderly patients exhibit heightened sensitivity to pethidine's effects, including respiratory depression and confusion, necessitating initiation at the lowest effective dose and vigilant observation.^[6] In pregnancy, potential risks to the fetus exist; it should be avoided during the third trimester and labor to prevent neonatal opioid withdrawal syndrome (NOWS) and prolonged normeperidine exposure in the newborn.^[6] Monitoring of vital signs, including respiratory rate and sedation level, is essential during pethidine administration to detect early signs of depression or overdose.^[1] Particular attention to seizure risk is required in patients with sickle cell disease, where normeperidine accumulation may precipitate convulsions even with normal renal function.^[45] For breastfeeding individuals, pethidine and its metabolite are excreted into breast milk, potentially causing infant sedation and respiratory depression; monitoring of the infant for drowsiness and feeding difficulties is recommended, with use limited to short durations if necessary.^[1] As of 2025, the FDA has issued a black box warning for pethidine highlighting its high potential for addiction, abuse, and misuse, which can result in overdose and death; healthcare providers must assess patients for opioid use disorder risk prior to prescribing.^[6]

Non-Medical and Recreational Use

Patterns of Abuse

Non-medical use of pethidine is primarily driven by its euphoric and sedative effects, which stem from its inhibition of dopamine and norepinephrine transporters, producing a rapid sense of pleasure and relaxation similar to cocaine-like mechanisms.^[37] Users often seek these effects to alleviate stress, pain, or emotional distress, leading to diversion from medical supplies such as hospital stocks or personal prescriptions.^[46] Injection of oral formulations, including crushed tablets or syrups, is a common method to enhance these effects, despite risks of vascular damage and foreign body emboli.^[47] Historical patterns of abuse are particularly prevalent among healthcare workers, such as nurses and midwives, who self-administer pethidine due to easy access in clinical settings.^[48] For instance, cases document escalation from legitimate postoperative use to frequent self-injection, often procuring vials through professional channels for personal use at work or home.^[46] Although pethidine has lower analgesic potency than heroin—requiring higher doses for comparable effects—its availability in medical environments facilitates misuse over street drugs.^[1] Pethidine carries a high addiction potential, classified as a Schedule II controlled substance due to risks of rapid tolerance development from its short duration of action, necessitating escalating doses for sustained effects.^[1] Withdrawal symptoms upon cessation include anxiety, insomnia, nausea, and restlessness, mirroring general opioid dependence syndromes.^[49] As of 2025, reviews highlight ongoing misuse challenges, including difficulties in distinguishing therapeutic intent from abuse in healthcare contexts.^[50] Common routes for non-medical use include intravenous administration for a rapid, intense high, often via diverted injectable forms or modified oral preparations, while oral ingestion provides milder sedative effects over longer periods.^[1] Abuse is frequently associated with polydrug use, where pethidine is combined with other substances like benzodiazepines or alcohol to potentiate euphoria or mitigate withdrawal.^[51]

Trends and Epidemiology

In the United States, pethidine (also known as meperidine) was a commonly prescribed and abused opioid during the 1970s, but recreational use declined sharply by the 2000s primarily due to growing awareness of its toxicity, including neurotoxic effects from its metabolite normeperidine, which can cause seizures and myoclonus.^[52] Data from the Drug Abuse Warning Network (DAWN) indicated a 39% decrease in emergency department mentions of meperidine abuse from 1,335 in 1990 to 806 in 1996, reflecting reduced overall opioid abuse reports relative to other drugs.^[53] This downward trend persisted into the late 1990s and early 2000s, with DAWN reports from 1997 to 2002 showing continued low and stable mentions amid rising abuse of other opioids like oxycodone.^[54] Diversion of pethidine remained relatively low compared to other opioids, but reported thefts and losses in the US increased by 16.2% between 2000 and 2003, rising from 32,447 dosage units to 37,687, primarily from pharmacies.^[55] Globally, patterns of abuse vary by region, with higher risks in areas of continued widespread medical prescription and less stringent controls, where opioid consumption remains elevated compared to Western countries.^[56] Demographically, pethidine abuse is disproportionately common among medical professionals, including physicians and nurses, who have greater access to the drug; for instance, 65% of 280 pethidine-dependent individuals admitted to a US psychiatric hospital were healthcare workers.^[52] This pattern holds internationally, with abuse often linked to occupational exposure rather than broad recreational seeking.^[50] As of 2025, pethidine abuse continues to raise concerns within the broader opioid crisis, particularly due to challenges in distinguishing legitimate therapeutic use from misuse, especially in healthcare settings where hundreds of abuse cases have been reported in regions like Turkey.^[50] Recent data indicate no major resurgence in recreational use, and it remains under monitoring by public health authorities as part of efforts to address opioid diversion and addiction.^[50]

Chemistry and Production

Chemical Structure and Properties

Pethidine, chemically known as meperidine, possesses the molecular formula C_{15}H_{21}NO_{2}.^[26] Its systematic IUPAC name is ethyl 1-methyl-4-phenylpiperidine-4-carboxylate.^[57] As a member of the phenylpiperidine class of compounds, pethidine features a central piperidine ring substituted at the 1-position with a methyl group, and at the 4-position with both a phenyl ring and an ethoxycarbonyl ester group; this ester moiety is essential for conferring its characteristic opioid receptor affinity and analgesic properties.^[26] Unlike naturally derived opioid alkaloids such as morphine, which originate from opium poppy extracts, pethidine is entirely synthetic in origin, marking it as one of the first fully artificial opioids developed for clinical use.^[5] In its free base form, pethidine appears as a white crystalline powder with a melting point of 270 °C.^[58] The compound exhibits moderate solubility in water (approximately 6 g/L at 25 °C) due to its lipophilic nature (logP ≈ 2.7), though the hydrochloride salt form—commonly used in pharmaceutical preparations—is freely soluble in aqueous media.^[58]^[57] The pKa of the hydrochloride salt is 8.7, reflecting the weakly basic character of the piperidine nitrogen, which influences its ionization and solubility profile at physiological pH.^[58] Pethidine demonstrates certain stability challenges in solution, particularly in intravenous admixtures, where degradation can occur over time depending on storage conditions such as temperature, light exposure, and diluent composition; studies indicate that concentrated solutions may require refrigeration to maintain potency beyond short-term use.^[59]

Synthesis Methods

Pethidine was first synthesized in 1937 by German chemist Otto Eisleb at the laboratories of IG Farbenindustrie as part of efforts to develop anticholinergic agents. The original synthesis involved condensation of benzyl cyanide with β,β'-dichloroethyl ether in the presence of sodium amide, followed by ring opening with halogen acid, treatment with methylamine for piperidine ring closure, hydrolysis to the carboxylic acid, and esterification with ethanol using sulfuric acid to yield ethyl 1-methyl-4-phenylpiperidine-4-carboxylate (pethidine). A simplified variant condenses benzyl cyanide directly with bis(2-chloroethyl)methylamine to form the key intermediate 1-methyl-4-cyano-4-phenylpiperidine, followed by hydrolysis and esterification.^[60] This method was patented by IG Farbenindustrie under German Patent 679,281 in 1937 and corresponding US Patent No. 2,242,575 in 1941, enabling scalable pharmaceutical production due to the availability of starting materials and straightforward reaction conditions.^[61] Modern industrial synthesis largely follows variations of Eisleb's approach to improve yield and safety, such as the 1944 method by Bergel et al., which utilizes β-chloroethyl vinyl ether and benzyl cyanide, followed by acid hydrolysis, treatment with thionyl chloride to form the acid chloride, reaction with methylamine for ring closure, saponification, and final esterification.^[60] Another variant, developed by Miescher and Kaegi in 1949 (US Patent No. 2,486,793), begins with α-phenyl-γ-(methyl-benzylamino)butyronitrile and ethylene dibromide using acid-binding agents, followed by heating to cyclize, saponification, and esterification; this route offers flexibility for large-scale operations by avoiding certain hazardous intermediates.^[60] These processes prioritize efficiency and precursor accessibility while maintaining high purity for medicinal use. Illicit synthesis of pethidine presents significant challenges due to the need for controlled or hazardous precursors, such as bis(2-chloroethyl)methylamine, a potent vesicant that risks severe skin and respiratory damage to handlers without proper equipment.^[60] Intermediates like normeperidine (1-phenyl-4-carbethoxypiperidine) or the 4-cyano-4-phenylpiperidine nitrile are also regulated under international conventions, complicating clandestine production and often resulting in low yields or impure product unsuitable for distribution.^[62]

Legal Status and Regulation

International Controls

Pethidine, also known as meperidine, is classified under Schedule I of the 1961 United Nations Single Convention on Narcotic Drugs, subjecting it to the most stringent international controls on production, manufacture, distribution, and use, limited exclusively to medical and scientific purposes.^[63] The International Narcotics Control Board (INCB) oversees global compliance and establishes annual manufacturing quotas to balance legitimate needs with diversion prevention; for instance, the global quota for pethidine was set at 7,500 kg in 2014, with continued declines in subsequent years, including reduced consumption as of 2023.^[64]^[65] The World Health Organization (WHO) removed pethidine from its Model List of Essential Medicines in 2003, citing its inferior safety and efficacy compared to alternatives like morphine, particularly due to risks of neurotoxicity from metabolite accumulation. As of 2025, WHO continues to monitor pethidine within the broader context of the opioid epidemic, promoting rational prescribing practices and strategies to minimize misuse, dependence, and overdose risks associated with all opioids.^[66] Under the 1961 Convention, international export and import of pethidine require separate authorizations from competent national authorities for each shipment, including import certificates from the receiving country and verification of medical necessity to prevent illicit trafficking.^[63] Additionally, the 1988 United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances controls precursor chemicals essential to pethidine synthesis, such as piperidine, listed in Table II, mandating record-keeping, licensing, and reporting for their international trade.^[67] These treaties establish a harmonized global framework, though parties may adopt stricter controls in response to pethidine's abuse potential, including its euphoric effects and risk of dependence akin to other synthetic opioids.^[65]

National and Regional Regulations

In the United States, pethidine (also known as meperidine) is classified as a Schedule II controlled substance under the Controlled Substances Act, indicating a high potential for abuse with accepted medical use under strict regulation.^[68] It is available only by prescription, with the Drug Enforcement Administration (DEA) imposing quotas on its production to limit supply; for instance, the aggregate production quota decreased by 91.6% from 10,168 kg in 2001 to 856.7 kg in 2020, with further reductions to 30 kg proposed for 2025, reflecting a broader decline in clinical use.^[69]^[70] Abuse is monitored through the DEA's prescription drug monitoring programs and reporting requirements for manufacturers and prescribers.^[71] In the United Kingdom, pethidine is designated as a Class A drug under the Misuse of Drugs Act 1971, subjecting it to the strictest controls on possession, supply, and production due to its potential for harm.^[72] Within the National Health Service (NHS), its use for labor pain relief is restricted, as National Institute for Health and Care Excellence (NICE) guidelines highlight limited efficacy and potential adverse effects on mother and baby, favoring safer alternatives like epidurals or remifentanil.^[73] In Australia, pethidine is categorized as a Schedule 8 controlled drug under the Poisons Standard, requiring special authorization for prescribing and dispensing to prevent misuse, with availability limited to acute pain management in hospital settings.^[74] Its use has declined significantly due to concerns over toxicity and inferior efficacy compared to alternatives like morphine, though it remains accessible for short-term relief. Similarly, in New Zealand, pethidine is a Class B3 controlled drug, with prescriptions monitored through real-time reporting systems and declining utilization for acute pain amid preferences for other opioids.^[75] As of 2025, the European Union has implemented enhanced monitoring and reporting mechanisms for opioids like pethidine to curb diversion, including mandatory electronic prescription systems and annual consumption data submissions to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), aligning with broader efforts to address opioid-related harms.^[76] In some Asian countries, such as Taiwan and Indonesia, pethidine is subject to strict controls as a Category 2 narcotic in Taiwan (as updated in 2025) and monitored clinical use in Indonesia due to high abuse potential and associated health risks, with guidelines limiting its availability to specialized settings.^[77]^[78]

History and Societal Impact

Development and Early Use

Pethidine, also known as meperidine, was developed in the late 1930s by German chemist Otto Eisleb at the IG Farben laboratories in Frankfurt as a potential anticholinergic agent intended as a synthetic alternative to morphine.^[79] Its analgesic properties were soon identified by pharmacologist Otto Schaumann, leading to a German patent in 1937 (DE 659943) and synthesis of the compound in 1938.^[26] This marked pethidine as the first fully synthetic opioid, distinct from natural opium derivatives, and it was initially pursued for its promise of effective pain relief with reduced side effects compared to morphine.^[1] The drug entered medical use in Germany in 1939, with early applications in obstetrics noted by 1940.^[80] In the United States, it received approval from the Food and Drug Administration in 1942 under the trade name Demerol for the management of moderate to severe pain, marketed as a safer option with lower addiction potential and fewer respiratory depressant effects than morphine.^[81] Initial adoption focused on surgical and postoperative settings, where its rapid onset and shorter duration of action were advantageous. Pethidine reached peak popularity from the 1950s through the 1970s, becoming the preferred opioid for labor analgesia and routine surgical pain control due to its versatility and perceived safety profile.^[82] However, recognition of risks associated with its metabolite norpethidine, which can accumulate and cause neurotoxicity including seizures, led to a decline in use as safer alternatives like morphine gained favor.^[83] Key milestones include its initial inclusion on the World Health Organization's Model List of Essential Medicines in the 1970s, followed by removal in 2003 due to inferior efficacy and toxicity compared to other opioids.^[84] As of 2025, pethidine's legacy endures as the pioneering synthetic opioid that paved the way for subsequent phenylpiperidine derivatives.^[85] Pethidine, marketed under brand names such as Demerol in the United States and Dolantin in various international markets, has appeared in popular media as a symbol of opioid dependency and the allure of prescription painkillers. In Michael Jackson's 1997 song "Morphine" from the album Blood on the Dance Floor: HIStory in the Mix, the lyrics repeatedly reference Demerol, portraying the singer's descent into addiction with lines like "Demerol, Demerol / Oh God, he's taking Demerol," drawing from Jackson's own documented struggles with the drug.^[86] Similarly, Irvine Welsh's 1993 novel Trainspotting and its 1996 film adaptation include pethidine in a famous monologue listing abused substances, underscoring its role in the underground drug culture of 1980s Edinburgh alongside heroin and other opioids.^[87] High-profile cases have further embedded pethidine in public consciousness regarding medical ethics and drug safety. In the UK, general practitioner Harold Shipman admitted in 1976 to forging more than 70 prescriptions for pethidine to sustain his personal addiction, marking an early scandal that highlighted vulnerabilities in healthcare professionals' access to controlled substances and foreshadowing his later convictions for patient murders.^[88] Across the Atlantic, the 1984 death of 18-year-old Libby Zion in New York Hospital resulted from a severe interaction between intramuscular pethidine and her prescribed MAOI antidepressant phenelzine, causing serotonin syndrome; this tragedy spurred the Libby Zion Law, mandating reforms in resident physician training, supervision, and work-hour limits to enhance patient safety.^[89] These events have influenced societal attitudes toward opioids, elevating pethidine's profile in awareness initiatives focused on abuse prevention and drug interaction risks. Its generic formulations, widely available since the mid-20th century, have amplified concerns about diversion and misuse, prompting inclusion in educational resources that emphasize safer alternatives for pain management.^[5] By 2025, pethidine features in broader opioid prevention campaigns as a cautionary example of synthetic analgesics' addictive potential and clinical hazards.^[1]

References

[1]
Meperidine - StatPearls - NCBI Bookshelf - NIH
The use of pethidine exposes patients and others to the risks of opioid addiction, misuse, and abuse, which can result in overdose and death.[25] Healthcare ...
[2]
Demerol: Is It the Best Analgesic? - Patient Safety Authority
In fact, studies found that the analgesic effects of meperidine are not pronounced, and that meperidine has unique side effects including serotonergic crisis ...
[3]
[PDF] This label may not be the latest approved by FDA. For current ...
The major hazards of meperidine, as with other opioid analgesics, are respiratory depression and, to a lesser degree, circulatory depression, respiratory arrest ...
[4]
Meperidine (pethidine) versus morphine in acute pain management ...
Aug 31, 2016 · The present study aimed to evaluate the effectiveness of morphine and meperidine (pethidine) as pain relief in opioid-dependent patients with acute pain.Missing: pharmacology | Show results with:pharmacology
[5]
Meperidine: Uses, Interactions, Mechanism of Action - DrugBank
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged ...Missing: injury | Show results with:injury
[6]
[PDF] 4028208 This label may not be the latest approved by FDA. For ...
Prolonged use of DEMEROL Injection during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and ...
[7]
Meperidine Injection: Package Insert / Prescribing Info - Drugs.com
Apr 15, 2024 · Adults: The usual dosage is 50 mg to 100 mg intramuscularly or subcutaneously, 30 to 90 minutes before the beginning of anesthesia. Elderly ...
[8]
Pethidine: Uses, Dosage, Side Effects and More | MIMS Hong Kong
Adult: 25-150 mg via IM or SC inj 4 hourly as needed; may also be given via slow IV inj at a dose of 25-50 mg, repeated 4 hourly as needed.
[9]
Parenteral opioids for maternal pain management in labour - PMC
Studies in New Zealand and the UK have revealed that more than 95% of hospitals surveyed routinely offered intramuscular pethidine (Lee 2004; Saravanakumar ...
[10]
Pain management for women in labour: an overview of systematic ...
IV morphine versus IV pethidine, Women satisfied with analgesia 3 days postpartum, 1 (141), RR 0.87, 95% CI 0.78 to 0.98, significantly fewer women in the IV ...
[11]
Parenteral opioids for maternal pain management in labour - PMC
Pethidine has been shown to significantly affect fetal heart rate variability, accelerations and decelerations during labour (Solt 2002). Changes in normal ...
[12]
Diverticulitis Treatment & Management - Medscape Reference
Oct 15, 2024 · Although early recommendations for pain management favored meperidine based on a theoretical risk of affecting bowel tone and sphincters, ...
[13]
Meperidine to manage pain related to diverticular disease
Aug 6, 2025 · ... anticholinergic agent but was soon discovered to have analgesic properties. Although meperidine's anticholinergic effects were demonstrated ...
[14]
Pharmacologic Options for Reducing the Shivering Response to ...
Jan 6, 2012 · For successful induction and maintenance of induced hypothermia, shivering, as well as other thermoregulatory responses, must be overcome.
[15]
Shivering Treatments for Targeted Temperature Management - NIH
Pharmacologic methods can effectively control shivering, but some have adverse effects, such that risks and benefits to the patient have to be balanced.
[16]
Is Pethidine Safe during Labor? Systematic Review - PMC - NIH
Intramuscular (IM) or intravenous (IV) pethidine at low doses, of up to 50 mg, is safe to administer during labor.
[17]
Effect of pethidine administered during the first stage of labor on the ...
Aug 5, 2025 · In her recent literature review, Reynolds (2011) stated that acidosis and respiratory depression in babies are maximised if pethidine is given ...<|separator|>
[18]
Meperidine pharmacokinetics and effects on physiologic parameters ...
Oct 1, 2020 · Administration of 0.5 mg/kg may provide short-term analgesia, however, the associated inconsistent and/or short-term adverse effects suggest ...
[19]
Pain Management--The Practical and the Promising - WSAVA2004
Oral. 0.1-3.0 ; Sustained release oral. 1.5-3.0 ; Pethidine. IV. Contraindicated in small animals ; IM or SC. 2-10 ; Methadone. Iv. 0.05-0.01.
[20]
Pronounced Declines in Meperidine in the US: Is the End Imminent?
Meperidine was removed from the World Health Organization's Model List of Essential medicines in 2003 [10] (Table 1). The American Geriatrics Society Beers ...Missing: reason | Show results with:reason
[21]
Basic opioid pharmacology: an update - PMC - PubMed Central - NIH
Opioid agonists bind to G-protein coupled receptors to cause cellular hyperpolarisation. Most clinically relevant opioid analgesics bind to MOP receptors in the ...
[22]
Fentanyl and Pethidine Are Antagonists on Muscarinic Receptors in ...
It is concluded that during high-dose fentanyl anaesthesia, fentanyl may bind to muscarinic receptors and thereby produce a central anticholinergic syndrome.
[23]
Tonic blocking action of meperidine on Na+ and K+ channels in ...
Meperidine blocks the Na+ channel in the same concentration range as the local anesthetic agent lidocaine (half-maximal inhibiting concentration, 172 microM) ...
[24]
Postoperative Management of Shivering: A Comparison of Pethidine ...
Like morphine, pethidine exerts its analgesic effects by acting as an agonist at the μ-opioid receptor (8). It also has an agonistic κ-opioid receptor action ...
[25]
Monoamine oxidase inhibitors, opioid analgesics and serotonin ...
The phenylpiperidine series opioids, pethidine (meperidine), tramadol, methadone and dextromethorphan and propoxyphene, appear to be weak serotonin re-uptake ...
[26]
Meperidine | C15H21NO2 | CID 4058 - PubChem - NIH
Following oral administration of meperidine, peak analgesia occurs within one hour and gradually declines over 2-4 hours. Peak analgesia occurs about 40-60 ...
[27]
Pharmacokinetics of high-dose meperidine in surgical patients
Intravenous meperidine is used during surgical procedures at doses up to 5 mg/kg. ... kg, and apparent volume of distribution 3.74 L/kg). The present results thus ...
[28]
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N ...
We conclude that normeperidine formation in human liver microsomes is mainly catalyzed by CYP2B6 and CYP3A4, with a minor contribution from CYP2C19.
[29]
A comparison of nalbuphine and meperidine in treatment ... - PubMed
The incidence of nausea and vomiting with meperidine was 22 per cent (95 per cent confidence interval 10 to 34 per cent) and with nalbuphine 20 mg the incidence ...
[30]
Meperidine: MedlinePlus Drug Information
Mar 15, 2024 · Meperidine may cause serious or life-threatening breathing problems, especially during the first 24 to 72 hours of your treatment and any time your dose is ...Missing: pharmacology | Show results with:pharmacology
[31]
[PDF] CII Demerol® (meperidine hydrochloride, USP) - accessdata.fda.gov
Other symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, ...
[32]
The effects of three graded doses of meperidine for spinal ... - PubMed
Common side effects were fatigue (27%), pruritus (20%), and nausea (7%). Seven patients had respiratory depression and seven had a decrease of systolic ...
[33]
[PDF] THE USE OF ESSENTIAL DRUGS
Dec 5, 1997 · A toxic metabolite of pethidine, norpethidine, accumulates during ... myoclonus and seizures. Morphine or alternative opioid analgesics ...<|separator|>
[34]
Norpethidine accumulation and generalized seizure ... - PubMed
Seizures associated with pethidine/norpethidine toxicity can occur early during pethidine usage, and there is considerable variation in measured norpethidine ...
[35]
The serotonin syndrome. Implicated drugs, pathophysiology and ...
The most common drug combinations causing the serotonin syndrome are monoamine oxidase inhibitors (MAOIs) and serotonin selective reuptake inhibitors (SSRIs), ...
[36]
Opioid‐induced inhibition of the human 5‐HT and noradrenaline ...
SERT inhibition by tramadol, tapentadol, methadone, dextromethorphan and pethidine may contribute to the serotonin syndrome.
[37]
Is Meperidine the Drug That Just Won't Die? - PMC - PubMed Central
In a study by Hamunen and colleagues of 20 4- to 8-year-old children, meperidine pharmacokinetic parameters were found to be similar to those reported in adults ...
[38]
Intravenous Oxycodone Versus Other Intravenous Strong Opioids for ...
Apr 19, 2019 · The unfavorable risk–benefit profile of pethidine has led to a gradual decline ... use of pethidine as an indicator of poor quality of care ...
[39]
Effects of obstetric analgesics and anesthetics on the neonate
Repeated maternal administration of opioids such as pethidine (meperidine) results in significant fetal exposure and neonatal respiratory depression.
[40]
The Effect of Pethidine Analgesia on Labor Duration and Maternal ...
Pethidine (Aldolan ™) decreases acute pain for 2-4 hours and is considered a good option to treated labor pain (11). However, the potential maternal and ...Missing: adjunct anxiety
[41]
[PDF] DEMEROL® TABLETS and ORAL SOLUTION - accessdata.fda.gov
Monitor patients receiving DEMEROL Tablets or Oral Solution, and any. CYP3A4 inhibitor or inducer [see Warnings and Precautions (5.6), Drug Interactions (7)].
[42]
Monoamine Oxidase Inhibitor (MAOI) Toxicity - Medscape Reference
Oct 25, 2023 · In 1984, an MAOI-meperidine interaction changed physician training in the United States. Libby Zion was a young woman admitted to a major ...
[43]
Drug-Induced Serotonin Syndrome - U.S. Pharmacist
Nov 17, 2010 · One notable case that garnered national attention was that of Libby Zion, an 18-year-old college freshman with a history of depression who was ...
[44]
Opioid analgesic drugs and serotonin toxicity (syndrome) - PubMed
Jun 18, 2018 · Reports of the involvement of individual opioids particularly tramadol, tapentadol, meperidine, methadone, oxycodone, fentanyl, and ...
[45]
[PDF] highlights of prescribing information - accessdata.fda.gov
Meperidine is contraindicated in patients who are receiving monoamine oxidase (MAO) inhibitors or those who have recently received such agents. Therapeutic ...
[46]
Meperidine | Drug Lookup | Pediatric Care Online - AAP Publications
A low-dose, low-potency, short-acting opioid can be used to treat acute pain associated with delivery when needed (ACOG 2021). Opioids are not preferred for the ...
[47]
Childhood adversity and co-dependency roles in a case of a midwife ...
Nov 17, 2022 · Pethidine addiction is common among healthcare workers (Mpewo, 2019). Doctors, nurses, and midwives who develop pethidine addiction, usually ...
[48]
Injection of crushed tablets—A prospective observational study
Aug 6, 2025 · Foreign body emboli, angiothrombosis, and pulmonary hypertension result from intravenous injection of oral pharmaceutical tablets. ... pethidine ...
[49]
A Nurse with Pethidine Addiction
Its opioid analgesic usage is legal, yet it is possible that it can be abused by the health care workers and addiction may become a frequent case. In order to ...Missing: patterns | Show results with:patterns
[50]
Withdrawal Management - NCBI - NIH
Patients commencing methadone maintenance treatment do not need to undergo withdrawal before commencing treatment. Opioid withdrawal syndrome. Short-acting ...
[51]
A Comprehensive Review of Pethidine, One of the Most Abused ...
Mar 1, 2025 · The abuse of this drug is most common in the health sector, which further increases the seriousness of the situation. This is thought to be due ...Missing: patterns | Show results with:patterns<|separator|>
[52]
Polydrug abuse: A review of opioid and benzodiazepine ...
This paper reviews studies examining the pharmacological interactions and epidemiology of the combined use of opioids and benzodiazepines (BZD).Missing: pethidine | Show results with:pethidine
[53]
Meperidine: A Continuing Problem - PMC - NIH
Meperidine has been referred to as “the doctors' and nurses' addiction”. 186 of a total of 280 pethidine addicts (65%) admitted to a US psychiatric hospital ...
[54]
Trends in medical use and abuse of opioid analgesics - PubMed
Reports of abuse decreased for meperidine (39%; 1335 to 806), oxycodone (29%; 4526 to 3190), fentanyl (59%; 59 to 24), and hydromorphone (15%; 718 to 609), and ...Missing: recreational global
[55]
A reassessment of trends in the medical use and abuse of opioid ...
Between 1997 and 2002, there was a 28% increase in the number of multi-drug episodes seen by DAWN EDs, which indicates increasing poly-drug use. It is possible ...Missing: pethidine | Show results with:pethidine
[56]
https://journal.waocp.org/article_25159_8af53ce0509b8962a61de46f05128110.pdf
[57]
[PDF] INTRODUCTORY LECTURES - Opioids in Middle Eastern Populations
Saudi Arabia; 447 times that in Turkey and 633 times that in Egypt. Meperidine (pethidine, demerol): The consumption of meperidine has been in a decline in the ...<|separator|>
[58]
pethidine | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Physico-chemical Properties. Click here for help. Physico-chemical Properties ... US FDA (1942). IUPAC Name Click here for help. ethyl 1-methyl-4 ...Missing: formula melting solubility<|control11|><|separator|>
[59]
MEPERIDINE | 57-42-1 - ChemicalBook
Dec 18, 2024 · MEPERIDINE Properties ; 1.0267 (rough estimate) · 1.5130 (estimate) · 11 °C · −20°C · pKa 8.7 (Uncertain).
[60]
Pethidine HCl | Drug Information, Uses, Side Effects, Chemistry
Meperidine hydrochloride is a white crystalline substance with a melting point of 186 C to 189 C. It is readily soluble in water and has a neutral reaction and ...
[61]
Pethidine stability in intravenous solutions - PubMed
Pethidine stability in intravenous solutions.
[62]
[PDF] Chemical Aspects - Europe PMC
(1) The first synthesis of pethidine by Eisleb 13 comprised the follow- ing ... 679,281, 8 August 1937). 15. Grewe, R. & Mondon, A. (1948) Chem. Ber. 81 ...Missing: Otto | Show results with:Otto
[63]
UNODC - Bulletin on Narcotics - 1954 Issue 2 - 007
... PETHIDINE. Details. Pages: 73 to 83. Creation Date: 1954/01/01. BIBLIOGRAPHY. Synthetic Drugs - I and II. INTRODUCTION. The following bibliography has been ...
[64]
[PDF] Precursors and chemicals frequently used in the illicit manufacture ...
Nov 1, 2017 · 4-phenylpiperidine, a chemical that the authorities suspected was being used in the synthesis of other opioids such as pethidine or ketobemidone ...<|control11|><|separator|>
[65]
[PDF] Single Convention on Narcotic Drugs, 1961
SCHEDULES. Revised Schedules including all amendments made by the Commission on Narcotic Drugs in. Force as of 5 March 1990. List of Drugs Included in Schedule ...
[66]
[PDF] Comments on the reported statistics on narcotic drugs - INCB
Dec 31, 2024 · In 2014, manufacture of pethidine was concentrated in the United States (42 per cent), Spain (32 per cent),. Slovakia (13 per cent) and China ...Missing: quotas | Show results with:quotas
[67]
Opioid overdose - World Health Organization (WHO)
Aug 29, 2025 · Opioids are commonly used for the treatment of pain, and include medicines such as morphine, fentanyl and tramadol. Their non-medical use, ...
[68]
[PDF] The International Drug Control Conventions - Unodc
United Nations Convention against Illicit Traffic in Narcotic. Drugs and Psychotropic Substances of 1988, ... Piperidine. Sulphuric acida. Toluene. The salts of ...
[69]
[PDF] Report of the International Narcotics Control Board for 2023
Jan 21, 2023 · INCB has been calling upon Governments to ensure the unimpeded international availability of these medicines and raising awareness of the ...
[70]
[PDF] Controlled Substances - Alphabetical Order
... Schedule, "CSCN" = Controlled Substance Code Number. Controlled Substances ... Demerol, Mepergan, pethidine. Meperidine intermediate-A. 9232. ||. Y.
[71]
Declines and pronounced regional disparities in meperidine use in ...
Jun 14, 2021 · The DEA's aggregate production quota for meperidine decreased 91.6% between 2001 (10,168 kg) and 2020 (856.7 kg, Figure S4). FIGURE 3 ...
[72]
Drug Scheduling - DEA.gov
Drugs, substances, and certain chemicals used to make drugs are classified into five (5) distinct categories or schedules depending upon the drug's acceptable ...Missing: Pethidine | Show results with:Pethidine
[73]
List of most commonly encountered drugs currently controlled under ...
Apr 1, 2025 · The following is a list of the most commonly encountered drugs currently controlled under the misuse of drugs legislation showing their respective ...
[74]
Labour pain relief: intramuscular opioids – pethidine and diamorphine
Pethidine can bring on involuntary muscle spasms, and so may not given to women who have high blood pressure caused by their pregnancy (Fortescue and Wee, 2005) ...
[75]
[PDF] Consultation: Prescription strong (Schedule 8) opioid use and ...
Between 2011 and 2015 there were. 2145 deaths associated with oxycodone, morphine, codeine, fentanyl, tramadol and/or pethidine compared with 985 due to heroin.Missing: essential | Show results with:essential
[76]
[PDF] Pethidine, Tablet, 50 mg (NOUMED) - NEW ZEALAND DATA SHEET
... half-life of about 3 to 6 hours in healthy subjects; the metabolite norpethidine is eliminated more slowly, with a half- life reported to be up to about 20 ...Missing: bioavailability | Show results with:bioavailability<|control11|><|separator|>
[77]
Understanding Europe's drug situation in 2025 – key developments ...
Jun 5, 2025 · The European Drug Report 2025 provides a snapshot of the drug situation in Europe based on the latest data available.Missing: pethidine meperidine diversion
[78]
[PDF] A Post-Marketing Study of Pethidine in Indonesia: Safety Profile
Feb 20, 2022 · Because pethidine is more likely to cause dependence and cognitive damage than other opioids, some countries and facilities have restricted ...<|control11|><|separator|>
[79]
Trends and characteristics of pethidine use in Taiwan: a six-year ...
The patient demographics and health care characteristics for pethidine prescriptions between 2002 and 2007 are shown in Table 4. Pethidine prescriptions tended ...<|separator|>
[80]
Bulletin on Narcotics - 1957 Issue 2 - 006 - UNODC
... I. G. Farben in Germany in 1939 (8), (9). Although this drug, now better known internationally as pethidine, is today generally accepted together with some ...Missing: Otto | Show results with:Otto
[81]
Are we willing to change? - 2000 - Anaesthesia - Wiley Online Library
Dec 24, 2001 · Pethidine was introduced in Germany in 1939 and was first employed in labour by Benthin (1940). Since its introduction, pethidine has been the ...
[82]
[PDF] This label may not be the latest approved by FDA. For current ...
DEMEROL (meperidine hydrochloride injection), for subcutaneous, intramuscular, and intravenous use, CII. Initial U.S. Approval: 1942 ... approved by FDA. For ...Missing: 1943 | Show results with:1943
[83]
Meperidine - LiverTox - NCBI Bookshelf - NIH
Apr 25, 2019 · Meperidine is a synthetic opioid which has been used widely for therapy of moderate-to-severe pain. Meperidine has not been linked to serum enzyme elevations ...
[84]
Norpethidine toxicity and patient controlled analgesia - PubMed
Patient-controlled analgesia (PCA) with i.v. opioids is prescribed increasingly. We report three cases of norpethidine toxicity in patients receiving pethidineMissing: decline 1980s
[85]
Barriers to Accessing Internationally Controlled Essential Medicines ...
7, 37 Similar abuse was found in studies in Ghana. Pethidine was removed from the WHO EML because it was considered inferior to morphine due to its toxicity ...
[86]
Brief History of Opioids in Perioperative and Periprocedural ...
German chemists synthesized meperidine (called pethidine in Europe) and found it to be an effective analgesic with or without anesthesia. Meperidine was later ...
[87]
ADDICTIVE DEMEROL REALLY IS A PAIN 'KILLER' - New York Post
with lyrics such as “Demerol. Demerol. Oh God, he's ...<|control11|><|separator|>
[88]
Trainspotting Script by John Hodge Based on the Novel by Irvine ...
... pethidine, pentazocine, buprenorphine, dextromoramide chlormethiazole. The streets are awash with drugs that you can have for unhappiness and pain, and we ...
[89]
Shipman was sacked for drug abuse | Harold Shipman - The Guardian
Jan 31, 2000 · Harold Shipman was sacked from a West Yorkshire practice in the 1970s for falsifying more than 70 prescriptions to feed his drug addiction.
[90]
Serotonin Syndrome and the Libby Zion Affair
At 3:30am, Libby received an intramuscular injection of 25mg of meperidine. Between 3:30am and 4:30am, her agitation increased, she was noted to be confused and ...Missing: pethidine MAOI